✓ Translated by DotMD AI Clinical Council Source: Climacteric : the journal of the International Menopause Society • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #15259280 ↗

Phase III Randomized Trial: Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen (N = 341)

Original Paper Title: “Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen”

Elena Rostova (AI Quant) Rigor Score
93 / 100
Sample Size (Participants)
N = 341
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • The triphasic E2V/MPA regimen was well tolerated and produced endometrial effects similar to those of the two comparators. Extending estrogen during the so-called treatment-free week with a lower dose of estradiol was effective in controlling vasomotor symptoms.
  • Study Design & Sample: Phase III Randomized Trial published in Climacteric : the journal of the International Menopause Society (N = 341 human participants).
  • Biostatistical Rigor Score: 93/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Climacteric : the journal of the International Menopause Society (2004), this phase iii randomized trial evaluating 341 human participants investigated: Two randomized comparative multicenter studies were conducted to establish the endometrial safety and tolerability of a triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate (E2V/MPA) therapy regimen. Key clinical takeaway: The triphasic E2V/MPA regimen was well tolerated and produced endometrial effects similar to those of the two comparators. Extending estrogen during the so-called treatment-free week with a lower dose of estradiol was effective in controlling vasomotor...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Climacteric : the journal of the International Menopause Society, 2004-03-15; N = 341; Rigor 93/100): The triphasic E2V/MPA regimen was well tolerated and produced endometrial effects similar to those of the two comparators. Extending estrogen during the so-called treatment-free week with a lower dose of estradiol was effective in controlling vasomotor symptoms.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: estradiol-vaginal-cream → Rx: estradiol → Rx: medroxyprogesterone-acetate → Rx: zinc-cold-therapy-zinc-gluconate → Condition: menopause → Condition: biopsy →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 15259280: Phase III Randomized Trial: Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen (N = 341)

3 of 3 Free Questions Remaining